{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreiajb5ctwmjobukk3iabj424mezig2fve6eqik7m274iyqzb4gl4a4",
    "uri": "at://did:plc:5ka4qkui7nvjms7idhte2m4o/app.bsky.feed.post/3mn7qknnbxvc2"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreiga7him4jyxng2o7zc3sx3qq6ll6y7dhiv457u2abeamdff7mbhv4"
    },
    "mimeType": "image/jpeg",
    "size": 151969
  },
  "path": "/2026/05/31/low-dose-nivolumab-extends-survival-trial-head-neck-squamous-cell-carcinoma-asco-2026/?utm_campaign=rss",
  "publishedAt": "2026-05-31T17:11:55.000Z",
  "site": "https://www.statnews.com",
  "tags": [
    "Biotech",
    "In the Lab",
    "Pharma",
    "ASCO",
    "Cancer",
    "global health",
    "Pharmaceuticals",
    "Policy",
    "research"
  ],
  "textContent": "Low-dose, low-cost immunotherapies may help patients in poorer countries access high-tech cancer treatments.",
  "title": "Ultra-low doses could bring costly cancer treatments to more patients in poorer countries",
  "updatedAt": "2026-05-31T17:12:00.000Z"
}